

Randomised trial of Paramedic Delivered FICB for hip fracture (RAPID2) trial Patient Notification

This patient notification contains information about the research trial called RAPID2.

RAPID2 is looking at the effectiveness of paramedics providing local anaesthetic injections for patients with a suspected broken hip.

What is the study about?

Each year in the UK, over 75,000 people fracture their hip. This is an exceedingly painful injury and patients are given pain relief by a paramedic and taken to hospital by ambulance. The pain relief given usually includes morphine. This may not always work very well, especially during movement and can lead to side effects such as confusion, nausea and reduced effort of breathing. These side effects can lead to delays to surgery and may need further treatment.

In the RAPID2 study, paramedics may give a local anaesthetic injection (known as **Fascia Iliaca Compartment Block** or **FICB**) to patients with an injured hip before they are transported to hospital. Giving this injection may provide better pain control and better long-term outcomes than the alternatives currently in use.

The aim is to test the safety and effectiveness of paramedics providing FICB pain relief to patients with suspected hip fracture prior to hospitalisation. Eligible patients will be randomly allocated to receive either FICB or standard care. The chances of a patient receiving either treatment are like rolling dice.

This research is led by Swansea University and has received government funding through the National Institute of Health Research Health Technology Assessment Programme (NIHR HTA) (<https://www.nihr.ac.uk/explore-nihr/funding-programmes/health-technology-assessment.htm>).

NHS Ethical approval has been granted by Wales Research Ethics Committee 4 (reference: 21/WA/0175/291853) and approval for the use of confidential patient data by the NHS Health Research Authority Confidentiality Advisory Group (21/CAG/0151).

What if there is a problem/question?

Further information can be found at the trial website: [RAPID 2 - Swansea Trials Unit](#)

If you have questions or concerns, please contact:

RAPID2 Trial Manager

Mark Kingston

ILS2, Swansea University Medical School, Swansea University, SA2 8PP

Email: rapid2@swansea.ac.uk

Telephone: 01792 606844

Chief Investigator

Professor Helen Snooks

Swansea University Medical School, Swansea University, SA2 8PP

Email: h.a.snooks@swansea.ac.uk

Thank you for taking the time to read this patient notification and for taking an interest in this research study.